Zobrazeno 241 - 250
of 947
pro vyhledávání: ''
Autor:
Ingeborg J. H. Vriens, Marc B. I. Lobbes, Annelotte C. M. van Bommel, Marjolein L. Smidt, Thijs van Dalen, Grard A. P. Nieuwenhuijzen, Henk Struikmans, Carolien H. Smorenburg, Adri C. Voogd, Liesbeth J. Boersma, Vivianne C. G. Tjan-Heijnen, Sabine Siesling
Publikováno v:
Breast cancer research and treatment, 162(2), 353-364. Springer
Breast Cancer Research and Treatment, 162(2), 353-364. Springer, Cham
Breast Cancer Research and Treatment
Breast Cancer Research and Treatment, 162(2), 353-364. Springer, Cham
Breast Cancer Research and Treatment
Purpose In this retrospective population-based cohort study, we analyzed breast MRI use and its impact on type of surgery, surgical margin involvement, and the diagnosis of contralateral breast cancer. Methods All Dutch patients with cT1–4N0–3M0
Autor:
Birgitte Bruun Rasmussen, Elisabeth D. Galsgaard, Louise Maymann Nitze, Martin W. Berchtold, Nanni Din, Vibe Luja Lund, Leif Christensen, Svetlana Panina
Publikováno v:
Nitze, L M, Galsgaard, E D, Din, N, Lund, V L, Rasmussen, B B, Berchtold, M W, Christensen, L & Panina, S 2013, ' Reevaluation of the proposed autocrine proliferative function of prolactin in breast cancer ', Breast Cancer Research and Treatment, vol. 142, no. 1, pp. 31-44 . https://doi.org/10.1007/s10549-013-2731-7
Breast Cancer Research and Treatment
Breast Cancer Research and Treatment
The pituitary hormone prolactin (PRL) has been implicated in tumourigenesis. Expression of PRL and its receptor (PRLR) was reported in human breast epithelium and breast cancer cells. It was suggested that PRL may act as an autocrine/paracrine growth
Publikováno v:
Breast Cancer Research and Treatment
In previous studies, we observed that regulation of expression of CD200, both on cells of a transplantable breast cancer, EMT6, and of the host, as well as of the receptor, CD200R in host mice, regulated local tumor growth and metastasis in immunocom
Publikováno v:
Breast Cancer Research and Treatment, 162, 541-548
Breast Cancer Research and Treatment, 162(3), 541. Springer New York
Breast Cancer Research and Treatment
Breast Cancer Research and Treatment, 162, 3, pp. 541-548
Breast Cancer Research and Treatment, 162(3), 541. Springer New York
Breast Cancer Research and Treatment
Breast Cancer Research and Treatment, 162, 3, pp. 541-548
Contains fulltext : 173131.pdf (Publisher’s version ) (Open Access) PURPOSE: Fibroglandular tissue may mask breast cancers, thereby reducing the sensitivity of mammography. Here, we investigate methods for identification of women at high risk of a
Autor:
Steven M. Butler, Lawrence Paszat, Joseph M. Anderson, Elzbieta Slodkowska, Eileen Rakovitch, Cindy Fong, Sharon Nofech-Mozes, Wedad Hanna, Refik Saskin, Dave P. Miller, Susan J. Robertson, Frederick L. Baehner, Michel Bonin, Steven Shak, Farid Jamshidian, Sandip SenGupta, Diana B. Cherbavaz, Leela Elavathil, Alan B. Tuck, Martin C. Chang, Prashant A. Jani
Publikováno v:
Breast Cancer Research and Treatment
Validated biomarkers are needed to improve risk assessment and treatment decision-making for women with ductal carcinoma in situ (DCIS) of the breast. The Oncotype DX® DCIS Score (DS) was shown to predict the risk of local recurrence (LR) in individ
Autor:
Seigo Nakamura, Koichiro Tsugawa, Shinobu Masuda, Takanori Ishida, Masaaki Kawai, Kenjiro Aogi, Ai Tomotaki, Kotaro Iijima, Naoki Niikura, Eriko Tokunaga, Takayuki Kinoshita, Hiroaki Miyata, Akemi Kataoka, Takayuki Iwamoto, Yutaka Tokuda, Keisei Anan, Naoki Hayashi, Hiraku Kumamaru, Hideji Masuoka
Publikováno v:
Breast Cancer Research and Treatment
Purpose The aim of this study was to investigate whether young age at onset of breast cancer is an independent prognostic factor in patients from the Japanese Breast Cancer Registry, after adjustment of known clinicopathological prognostic factors. M
Autor:
Suhail M. Ali, Yuping Tan, Allan Lipton, Christian F. Singer, Jeffrey S. Larson, Thomas Sherwood, Reinhard Horvat, Gordon Parry, Mojgan Haddad, A. Paquet, Jeff Sperinde, Kim Leitzel, Yolanda Lie, Xueguang Jin, John Winslow, Ahmed Chenna, Weidong Huang, Yining Shi, Joyee Banerjee, Jodi Weidler, Jennifer W. Cook, Wolfgang J. Köstler, Michael Bates, Alicia Newton, Ali Mukherjee, Eva Marie Fuchs, Laurie Goodman, Christos J. Petropoulos, Stephen Williams
Publikováno v:
Breast Cancer Research and Treatment
Trastuzumab is effective in the treatment of HER2/neu over-expressing breast cancer, but not all patients benefit from it. In vitro data suggest a role for HER3 in the initiation of signaling activity involving the AKT–mTOR pathway leading to trast
Publikováno v:
Breast Cancer Research and Treatment
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) has demonstrated clinical benefit in metastatic breast cancer (MBC) in a randomized phase III trial versus paclitaxel (CA012; N = 454) and in a randomized phase II trial versus docetaxel (CA024;
Autor:
Anke Thomas, Sherko Kümmel, Stefan Paepke, Marion Kiechle-Bahat, Ralf Ohlinger, Nadia Harbeck, Mathias Warm, Volker R. Jacobs
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 133(12):905-916
Several large, well-controlled clinical trials have now established that the aromatase inhibitors (AIs), including letrozole, anastrozole, and exemestane, are more effective than tamoxifen when used as adjuvant endocrine therapy in postmenopausal wom
Autor:
Vodermaier, Andrea, Linden, Wolfgang, Rnic, Katerina, Young, Sandra N., Ng, Alvina, Ditsch, Nina, Olson, Robert
Publikováno v:
Breast Cancer Research and Treatment
Psychological factors may influence survival in breast cancer patients but results of previous research are inconclusive. This prospective population-based study tested whether depression predicts mortality in breast cancer patients. Routinely collec